10 organized a thorough investigation in October, and 190 pharmaceutical companies received the most attention.

Affected by the disclosure window of the third quarterly report, the number of institutional research companies has decreased. The data shows that in June, 5438+ 10, institutions investigated 190 companies, only one-third of the same period of last month; Among them, 1 16 companies were investigated by more than 10 institutions, less than half of the same period last month. From the perspective of industry, pharmaceutical bio-stocks are most concerned by institutions.

10 institutional research 190 shares

10, the just-concluded trading day is the disclosure month of listed companies in the third quarter of 2020. As a result, the number of companies surveyed by institutions has decreased significantly. According to the straight flush iFinD statistics, there were only 190 companies surveyed by institutions in June, with 438+00, which was only 34.86% of the 545 companies in the same period in September. Among them, 1 16 companies were investigated by more than 10 institutions, accounting for only 48.95% of 237 companies in the same period.

Among them, Goer (00224 1), Hikvision (0024 15), Guanglianda (0024 10), Huace Testing (3000 12) and Changchun High-tech (0006/kloc).

The most concerned by institutions is Goer shares. According to the data, in May of 5438+ 10, the company received 330 institutions including 1 10 Public Offering of Fund, 37 brokers, 33 sunshine private placements, 39 overseas institutions and 23 insurance companies. In the survey, Goer shares are optimistic about the future trend of its main business sectors. For example, in the component business, in addition to the traditional precision component business, the company also actively expands related component business, including acoustic-related touch, wireless charging and other component business, SiP product business representing the future direction, and optical and precision structural parts.

Behind the threshold being broken by many institutions is that Goer's third quarterly report exceeded expectations. The third quarterly report shows that Goer shares achieved revenue of 34.73 billion yuan in the first three quarters, a year-on-year increase of 43.9%; The net profit returned to the mother was 206,543,806 yuan, up 65,438+004,438+0% year on year; Among them, the company achieved a net profit of 65.438+0.236 billion yuan in the third quarter, a year-on-year increase of 654.38+0.67.92%. In addition, Goer shares predict that the net profit returned to the mother in 2020 will be about 2.753 billion yuan -28.8 1 billion yuan, up 65.438+015.0%-65.438+025.0% year-on-year. The increase in performance is mainly due to the increase in sales revenue of the company's smart wireless headsets (TWS headsets), precision components, virtual reality and other related products.

In addition, Aibo Medical (688050), Yizhimi (3004 15), Lu Hong Steel Structure (00254 1), Iflytek (002230), Polaiya (603605) and Shuangta Food (00248/kloc). Jinbo (688598), Huadong Pharmaceutical (000963), Shangpin ZJS (3006 16), Yuxin Technology (300674), Shiyuan (00284 1), Luopu Pharmaceutical (00739), Zhengbang Technology.

Judging from the number of institutional research, Hao Yun Science and Technology is the company with the most intensive institutional research. According to the data, Hao Yun Science and Technology was investigated by six groups of institutions from June+10, 5438. Yonggao Co., Ltd. (00264 1) and Hanwang Technology (002362) were both investigated by institutions for four times, and tied for second place. In addition, Desai Siwei, Lu Hong Steel Structure (00254 1), Jinbo (688598), Chujiang New Materials (002 17 1), Zhongtian Hardcover (002989) and Hanzhong Seiki (0021).

Medical and biological stocks are the most concerned.

According to the industry of the research company, the listed companies surveyed by the organization in June 5438+ 10 mainly concentrated in pharmaceutical biology (24 companies), electronics (2 1 home), computers (17 companies), mechanical equipment (16 companies) and chemical industry (. Obviously, medical biology was the most popular among the institutional surveys from June to 10 in 5438.

Han Guangzhe, equity fund manager of Golden Eagle Medical and Health Industry, said that after short-term adjustment, pharmaceutical companies in the A-share market have partially digested the high valuation pressure and will stick to tracking key pharmaceutical companies from the bottom up. Zhuang Hongdong, the manager of cheese fund, said that at the beginning of the year, the valuation of pharmaceutical stocks was not high and the performance was highly certain. Under the catalysis of the epidemic, the market is very big. However, the contribution of the epidemic to the performance of related companies is only one or two quarters, not a continuous contribution.

Torrent, the hybrid fund manager of Harvest Ruixi's three-year closed operation, said in the third quarterly report that the allocation ratio of some listed pharmaceutical companies with excessive cumulative increase was reduced. The third quarterly report on flexible allocation of Rongtong health industry shows that fund managers choose tracks and stocks with good growth and relatively low valuation for key allocation, so as to reduce the allocation of related targets that have great damage to medical insurance control fees. The mentality of holding shares in the middle line is to wait calmly, exchange time for space and adjust the portfolio structure in a timely manner.

However, some fund managers chose to increase their positions in pharmaceutical stocks in the third quarter. In the third quarterly report, the equity fund manager of the medical and health industry of ICBC Credit Suisse said that in the adjustment of pharmaceutical stocks in the third quarter, the fund seized the opportunity to moderately increase its positions. Structurally, we maintained the core positions in long-term promising fields such as innovative drugs, innovative medical devices and CDMO, and reduced the positions in sub-fields that benefited from the epidemic.

The manager of Huaxia Medical and Health Mixed Fund believes that medicine is an industry worthy of long-term investment, and the aging population and the development of economic level in China constitute the long-term support of the pharmaceutical industry from demand to payment. Therefore, in the process of building a portfolio, we should also base ourselves on the long term and choose enterprises with space, business model barriers or competitive advantages to invest in order to bring stable returns to investors. In the selection of pharmaceutical sub-industries, the combination construction will combine long-term space and prosperity, comprehensively consider factors such as valuation, and try to choose relatively scattered sub-industries to avoid exposing too many risks in a single driving factor.

Hu Rongquan, manager of Guolian Anrui Growth Fund, said that in the long run, the pharmaceutical industry has great room for growth in the future. The core is that the penetration rate of various drugs and devices is still very low. With the continuous improvement of the innovation ability of superimposed enterprises, more demands will be created one after another. At present, the market has gradually reflected this long-term trend in the future. The valuation of core stocks is generally high, so investment in the pharmaceutical industry should pay more attention to the industry trajectory and the certainty of growth, and the holding period may be longer.

5438+ 10 at least 30 companies surveyed by institutions.

This article comes from Fortune Power Network.